Intensive gliclazide has long-lasting kidney benefits
Intensive glucose control in patients with type 2 diabetes leads to reductions in kidney failure many years after return to usual care, say Australian researchers.
Their global study shows reduced renal failure risk five and a half years after patients with type 2 diabetes ended an intensive glucose lowering regimen based on gliclazide MR.
They report less need for dialysis or transplantation without any change to the risks of death or cardiovascular disease.
Led by The George